A new portfolio model for biotech
“Until recently, biotech companies tended to be founded with a focus on a single technology or biological pathway…Over the past five years, however, an innovative business model has merged for biotech. In it, a portfolio manager…”
In Mckinsey & Company’s latest article, A new portfolio model for biotech, the emerging portfolio model is explored on how it is disrupting the biopharma industry.
About Biojo Sciences
Biojo Sciences is a global biopharmaceutical company developing novel clinical-stage therapies that improve patient and family lives. With locations in Bethesda, Maryland, and Seoul, South Korea, we in-license, invest, and develop promising clinical-stage drug assets.
